Trials / Completed
CompletedNCT07008963
Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
A Non-interventional, Observational Qualitative Interview Study of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 48 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | non-interventional | This is a non-interventional, observational study |
Timeline
- Start date
- 2025-07-31
- Primary completion
- 2025-11-28
- Completion
- 2025-11-28
- First posted
- 2025-06-06
- Last updated
- 2026-02-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07008963. Inclusion in this directory is not an endorsement.